GPAT QUESTION PAPER 2005 WITH ANSWER KEY

PHARMACEUTICAL SCIENCE

| | | PHARMACEU | LICAL | SCIENCE | | |
|-----|--------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------------|--|
| Tin | ne : 3 hours | | · - | | Maximum Marks: 150 | |
| | | (Q. 1 - 30) CARRY | the type of powder flow is (c) Very poor (d) Good (b) Rotating cube mixer (d) Fluidized bed mixer the drying process used is ying (c) Drum drying (d) Freeze drying It in an aqueous system, is (b) \alpha-Tocopherol (d) Phenol adding of the coating solution before drying causes feet (c) Blistering effect (d) Picking effect ristics show that the Rauwolfia serpentine is adulterated with (b) Cluster crystals of calcium oxalate (d) Unlignified pericyclic fibres Inquished from Indian rhubarb by fluorescence developed in the identification of leaf drugs remainconstant throughout (b) Veinlet termination number (d) Stomatal Index erase undergoes hydrolysis in solution togive methyl carbamic | | | |
| 1. | If the Carr's index of a | powder is 10 % then the ty | ype of p | owder flow is | | |
| | (a) Poor | (b) Excellent | | | (d) Good | |
| 2. | Mixing of semisolids is | . , | () | | | |
| | (a) Double cone mixer | • | (b) | Rotating cube mix | er | |
| | (c) Planetary mixer | | (d) | Fluidized bed mix | er | |
| 3. | In the preparation of s | mall pox vaccine, the dryin | ng proce | ess used is | | |
| | (a) Spray drying | (b) Vacuum drying | (c) | Drum drying | (d) Freeze drying | |
| 4. | In cosmetic preparatio | ns, an oxidant used in an a | queous | system, is | | |
| | (a) Sodium formaldehy | yde sulphoxylate | (b) | α-Tocopherol | | |
| | (c) Methyl paraben | | (d) | Phenol | | |
| 5. | In tablet coating proces | ss, inadequate spreading of | f the co | ating solution befo | re drying causes | |
| | (a) Orange peel effect | (b) Sticking effect | (c) | Blistering effect | (d) Picking effect | |
| 6. | Presence of one of the | following characteristics | show th | at the Rauwolfia s | 0 () | |
| | other species of Rauwo | olfia. | | | | |
| | (a) Compound starch | grains | (b) | Cluster crystals of | calcium oxalate | |
| | (c) Lignified sclerides | | (d) | Unlignified pericy | clic fibres | |
| 7. | Chinese rhapontic rhu | abarb can be distinguishe | shed from Indian rhubarb by fluorescence developed in | | | |
| | UV light which is | | | | | |
| | (a) Deep yellow | (b) Deep violet | (c) | Green | (d) Blue | |
| 8. | Citrus flavonoids are ri | ch in | | | | |
| | (a) Aesculetin | (b) Fraxin | (c) | Hesperidin | (d) Scopoletin | |
| 9. | The quantitative value | es determined for the ide | entifica | tion of leaf drugs | remainconstant throughou | |
| | the age of plant EXCEP' | Γ | | | | |
| | (a) Stomatal number | | (b) | Veinlet termination | n number | |
| | (c) Veinislet number | | (d) | Stomatal Index | | |
| 10. | The alkaloid which inh | ibits the cholinesterase ur | ndergoe | s hydrolysis in solu | ition togive methyl carbamic | |
| | acid and eseroline is | | | | | |
| | (a) Scopolamine | (b) Pyridostigmine | (c) | Neostigmine | (d) Physiostigmine | |
| 11. | Luminescence is the ter | rm applied to | | | | |
| | (a) Absorbed radiation | n | (b) | Re-emission of pr | eviously absorbed radiation | |
| | (c) Excited radiation | | (d) | Transmitted radia | tion | |

| 12. | Polarogram of a solution containing an electro-reduc | ible substance is obtained byplotting |
|-----|----------------------------------------------------------|-------------------------------------------------------|
| | (a) Current vs. Volume | (b) Current vs. Potential |
| | (c) Resistance vs. Time | (d) Potential vs. Volume |
| 13. | Silica gel used in most of the absorbent columns con | tains -OH groups. So it is |
| | (a) Basic | (b) Neutral |
| | (c) Acidic | (d) Both acidic and basic |
| 14. | The electronic transition possible in Br ₂ is | |
| | (a) σ-σ* | (b) $\sigma - \sigma *$ and $n - \sigma *$ |
| | (c) $\sigma - \pi^*$ and $\pi - \pi^*$ | (d) $n - \pi^*$ and $\sigma - \pi^*$ |
| 15. | Ferrous ion is very weakly colored for colorimetric | analysis. It can be converted into a highly colored |
| | complex using | |
| | (a) H ₂ SO ₄ | (b) PDAB |
| | (c) Thymol blue | (d) 1:10-Phenanthroline |
| 16. | Prazepam, Oxazepam, Clonazepam are structurally s | imilar and have the system |
| | (a) 5H-Dibenz (b, f) azepine | (b) 1,2,4-Benzothiadiazepine |
| | (c) Benzodiazepine | (d) Phenothiazine |
| 17. | 11 β, 21-Dihydroxy pregn-4-ene-3,18,20-trione is | |
| | (a) Aldosterone | (b) Progesterone |
| | (c) Cholesterol | (d) Cortisone |
| 18. | 4, 7-Dichloroquinoline on treatment with 4-amino p | henol gives |
| | (a) 7-chloro-2-(2-hydroxy phenyl amino) quinoline | |
| | (b) 7-chloro-4-(4-amino phenyl) Quinoline | |
| | (c) 7-chloro-4-(4-hydroxy phenyl amino) quinoline | |
| | (d) 4-chloro-7-(4-Hydroxy phenyl amino) quinoline | |
| 19. | Ecgonine, a hydrolytic product of cocaine on treatment | nt with chromium trioxide gives a keto acid, which on |
| | thermal decarboxylation results in | |
| | (a) Atropic acid (b) Tropic acid | (c) Pseudo cocaine (d) Tropinone |
| 20. | A natural product derivative developed as an antima | |
| | (a) Artemether (b) Paludrine | (c) Pyrimethamine (d) Halofantrine |
| 21. | 'Ternary complex' refers to the state when | |
| | (a) An enzyme forms a covalent complex with its su | |
| | (b) An enzyme forms a non covalent complex with | • |
| | | or more substrates, is concurrently complexed with |
| | both substrates | |
| | (d) An enzyme complexed to a product, just after ca | • |
| 22. | The most important clue that helped in the determ | nination of the double helicalstructure of DNA came |
| | from | |
| | (a) Chargaff's rules | (b) Hershey-Chase experiment |

(d) Nirenberg and Khorana's codon assignments

(c) Avery-MacLeod-McCarty experiment

| 23. | Diversity in antibody mol | ecules is brought about by | | | | | |
|-----|---------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------|-------------------------------------------|-------|----------------|--|
| | (a) Post-translational mo | difications | (b) | Gene rearrangement | S | | |
| | (c) Usage of special gene | etic codes | (d) | d) Multiple mutations in the polypeptides | | | |
| 24. | The etiological agent of in | so as | associated with a form of Burkitt's lymphoma is | | | | |
| | (a) Varicella Zoster Virus | S | (b) | Epstein Barr Virus | | | |
| | (c) Picorna Virus | | (d) | Papovavirus | | | |
| 25. | Tissue plasminogen activa | ator that disperses blood cl | ots, l | eneficial if it is given | withi | in | |
| | (a) 3 days | (b) 9 hours | (c) | 3 hours | (d) | 24 hours | |
| 26. | An anticholinestrase which is useful in Alzheimer's disease is | | | | | | |
| | (a) Arecoline | (b) Donepezil | (c) | Isoproterenol | (d) | Clioquinol | |
| 27. | A drug is used as an opht | halmic solution in Herpes l | kerat | its is | | | |
| | (a) Zakitabine | (b) Trifluridine | (c) | Ritonavir | (d) | Stavudine | |
| 28. | A macrolide antibiotic use | ed as a powerful immunos | uppr | essive agent is | | | |
| | (a) Erythromycin | (b) Azithromycin | (c) | Tacrolimus | (d) | Clarithromycin | |
| 29. | Cytosine arabinoside acts | on this phase of the cell cy | /cle | | | | |
| | (a) G ₁ | (b) G ₂ | (c) | M | (d) | S | |
| 30. | The chairman of the Drugs Technical Advisory Board is | | | | | | |
| | (a) The drugs Controller of India | | | | | | |
| | (b) The Director, Central Drugs Laboratory, Kolkata | | | | | | |
| | (c) The President, Pharmacy Council of India | | | | | | |
| | (d) The Director General | of Health Services | | | | | |
| 31. | Predict the product obtained by treating 6 – chloro-3,5-daimino pyrazin-2-methyl carboxylate with | | | | | | |
| | Guanidian | | | | | | |
| | (a) Amilofide | | (b) | Hy droch loroth iazide | | | |
| | (c) Triamterene | | (d) | Furosemide | | | |
| 32. | 2-hydroxy-5,9-dimethyl-6,7-benzomorphane derivative is | | | | | | |
| | (a) Pentazocine | | (b) | Hydrocodone | | | |
| | (c) Codeine | | (d) | Buprenophine | | | |
| 33. | The raw materials used for the synthesis of Sulfalen are | | | | | | |
| | (a) 4-acetamido benzene sulfonyl chloride and 2-amino-4-methly pyrimidine | | | | | | |
| | (b) 4-acetamido benzene | sulfonyl chloride and 5-am | ino-2 | 2-ethly-1,3,4-thiadiazo | le | | |
| | (c) 4-acetamido benzene sulfonyl chloride and 5-amino-3,4-dimethly isoxazole | | | | | | |
| | (d) 4-acetamido benzene | sulfonyl chloride and 3-an | ino- | 2-methoxy pyrazine | | | |
| 34. | Phexon benzamine can b | e prepared from | | | | | |
| | (a) Phenol and propylen | e oxide | (b) | 3-phenylpropanol | | | |
| | (c) Phthalic anhydride | | (d) | b-phenyl succinic aci | d | | |

| 35. | Glyeyrrhizin, a sweet principalof liquorice is | |
|-----|---------------------------------------------------------------------------------------|--------------------------------------------------------|
| | (a) K and Mg salts of glycyrrhizinic acid | (b) Na and Mg salts of glycyrrhetinic acid |
| | (c) K and Ca salts of glycyrrhizinic acid | (d) Na and Ca salts of giycyrrhetinic |
| 36. | Alloploids are polyploids derived from | |
| | (a) A single parental species genomes | (b) More thanone parental species genomes |
| | (c) A plantwith haploid number of chromosomes | (d) A plant with diploid number of chromosomes |
| 37. | The most effective method for producing virus-free | plants is |
| | (a) Root culture | (b) Meristem culture |
| | (c) Somatic embryogenesis | (d) Floriculture |
| 38. | A person Taking organic nitrate has to avoid one of t | the following drugs as it can cause severe hypotension |
| | (a) Aspirine (b) Cholestyramine | (c) Warfarin (d) Sildenafil |
| 39. | To avoid lithium toxicity,a patient using lithium car | rbonate for mood disorders should not be prescribed |
| | (a) Acetazolamide | (b) Hydrochlorthiazide |
| | (c) Mannitol | (d) Porpranolol |
| 40. | A selective serotonin reuptake inhibitor used as an | antidepressant is |
| | (a) Venlafaxine (b) Selegiline | (c) Phenelzine (d) Amoxapine |
| 41. | A patientreceiving Digoxinfor CCF is found tohav | e elevatedserumcholesterol. Which hypolipidemic |
| | agent should not be prescribed | |
| | (a) Clofibrate (b) Cholestyramine | (c) Lovastatin (d) Niacin |
| 42. | In the study of enzyme kinetic, \boldsymbol{V}_{\max} is said to be attain | ed when |
| | (a) There is an excess of free enzyme as compared | to the substrate |
| | | yme-substrate complex and concentration of the free |
| | enzyme is vanishingly small http://www.xamst | • |
| | (c) The maximum velocity of the reaction in the pre | |
| | (d) When the concentration of free enzyme equals to | , |
| 43. | Serum sampleof apatient shows elevated levels of g | g-glutamyl transerase. The patient could be suffering |
| | from | 45 |
| | (a) Kidney disorder | (b) Liver disease |
| | (c) Parkinson's disease | (d) Myocardial infraction |
| 44. | Acid-fast organisms are seen in the sputum of a 48-y | |
| | needs long-term multi-drug treatment for tuberculos | |
| | (a) Chest X-ray | (b) Ziehl-Neelsen stain of the sputum |
| 45 | (c) Sputum cytology | (d) Mycobacterial cultures of the sputum |
| 45. | The distinguishing feature in IR spectra between pro | |
| | (a) Weak-CH stretching and out of plane bending in | propionaldenyde |
| | (b) Keto group in acetone | |
| | (c) Two methyl group acetone | |
| | (d) -CH, group in propionaldehyde | |

| 46. | Nephelometrical measu | rement are most sensitive fo | r | | | | |
|-----|-----------------------------------------------------------------------------|---------------------------------|-------|------------------------|----------------------|------------------|------|
| | (a) Clear solution (b) | | (b) | Concentrated solution | | | |
| | (c) Thick suspensions | | (d) | Very dilute suspe | nsion | | |
| 47. | Thenumber of peaks sh | ownby diethyl ether in an N | MR s | pectrum are | | | |
| | (a) Four | (b) Two | (c) | One | (d) Fiv | е | |
| 48. | The half-life for a zero of | order reaction is calculated us | sing | | | | |
| | (a) $t_{1/2} = 0.693/k$ | (b) $t_{1/2} = 2.303/k$ | (c) | t _{1/2} =1/ak | (d) t _{1/2} | =a/2k | |
| 49. | The biological half-lifeo | f procaine in patient was 35 r | ninu | tes and its volume | of distri | bution was estim | ated |
| | to be 60 L. The total clear | arance rate of procaine is | | | | | |
| | (a) 1.1881L/min | (b) 0.115L/min | (c) | 11.5L/min | (d) 5.5 | 7L/min | |
| 50. | The ratio of the void vo | lume to the bulk volume of t | he pa | acking of the powe | der is cal | led as | |
| | (a) Porosity (1 | b) True density | (c) | Granular density | | (d) Bulk density | 7 |
| 51. | A co-solvent used in the | e preparation of parenteral p | prod | ucts is | | | |
| | (a) Benzyle alcohol (l | b) Methyl alcohol | (c) | Dimethyl acetami | ide | (d) Phenol | |
| | | (Q.52-5 | 58) | | | | |
| | MULTIPLE SELECTION ITEMS.P,Q,R,S ARE OPTION.TWO OF THESE OPTIONARE CORRECT. | | | | | | |
| | сноо | SEN THE CORRECT COMBIN | NATI | ON AMONG A,B,C | AND D. | | |
| 52. | In mass spectroscopy,positively charged ionsbe produced by | | | | | | |
| | (P) Heating of the sample | | | | | | |
| | (Q) Bombarding the sa | mple with high energy electro | ons | | | | |
| | (R) Bombarding the sa | mple with highenergy proto | ns | | | | |
| | (S) Chemical ionisation | 1 | | | | | |
| | (a) Q, S (1 | b) Q, R | (c) | P, R | (d) | P, S | |
| 53. | A plastisizer and ahigh | boiling point solvent used in | the | preparation of nai | l lacquei | rs are | |
| | (P) Butyl stearate | | (Q) | Ethyl lactate | | | |
| | (R) Ethyl alcohol | | (S) | Acetone | | | |
| | (a) P, Q (1 | b) Q, S | (c) | R, S | (d) | Q, R | |
| 54. | Two of the following at | tributes are true for describi | ng | | | | |
| | (P) Neuromuscular blo | cking causing spastic paralys | sis | | | | |
| | (Q) Blocks the respons | e of the Ascaris muscle to AC | Н, са | nusing flaccid para | lysis in t | he worms | |
| | (R) Inhibits the Helmin | th specific enzyme fumarate | redu | ıctase | | | |
| | (S) Arrest nematode ce | ell divisions in metaphase by | inte | rfering with micro | tubule as | ssemble | |
| | (a) P, Q | b) P, R | (c) | Q, S | (d) | Q, R | |
| 55. | The colour and flavor o | f saffron are due to – | | | | | |
| | (P) Crocin (| Q) Crocetin | (R) | Safranal | (S) | Crepenyic acid | |
| | (a) R, S (1 | b) P, R | (c) | Q, S | (d) | Q, R | |

56. Predict the two impurities which are likely to be present in Glipizide (P) 5-methyl-N-[2-(4-sulphamoyl phenyl ethyl] pyrazin-2- carboxamid (Q) 5-methyl-N-[2-(2-sulphamoyl phenyl] pyrazine-2-carboxamide (R) Cyclohexanamine (S) Cyclohexane (a) P, R (b) P, Q (c) R, Q (d) R, S 57. Calcipotrience, synthetic vitamin D₂ analogue has the following attributes (P) Pronounced antirachitic activity (Q) Inhibits epidermal sell proliferation and enhances cell differentiation (R) Used as a topical application in the treatment of moderate plaque psoriasis (S) Effect on calcium metabolism is 200 times more than Ergocalciferol (a) Q, R (b) P.Q (c) R, S (d) Q, S 58. Insulin when released from the pancranic b cells (P) Can sequester blood glucose by forming a complex with it. (Q) Gets full conjugated with glucuranic acid immediately, to be released upon suitable stimuli in normal health. (R) Acts on the transporter molecules to facilitate glucose movement across the cell membranes (S) Increases storage of glucose to glycogen in the liver (a) R, S (b) P, R (c) Q, S (d) Q, P (Q. 59-65) ARE "MATCHING" EXERCISES. MATCH GROUP I WITH GROUP II CHOOSE THE CORRECT COMBINATION AMONG THE ALTERNATIVES A,B,C AND D. 59. **Group-I** Group- II (P) Ascrobic acid (1) TBAH (Q) Pyridoxine HCI (2) Iodine (R) Dapsone (3) HCIO, (S) Fluorouracil (4) Sodium nitrite (a) P-1, Q-4, R-3, S-2 (b) P-1, Q-4, R-3, S-2 (c) P-4,Q-2, R-1, S-3 (d) P-3,Q-2, R-4, S-1 60. Group-I Group- II Umbelliferous fruit Diagnostic character (P) Fennel (1) Wavy sclerenchyma (2) Branched and unbranched vittae (Q) Indian Dill (R) Coriander (3) Reticulately lignified parenchyma (S) Anise (4) Lateral ridges with vascular bundles

(b) P-3, Q-4, R-1, S-2

(d) P-4, Q-1, R-2, S-3

(a) P-1, Q-2, R-3, S-4

(c) P-2, Q-3, R-4, S-1

61. Group-I

Enzyme systems responsible for

Phase 2 conjugation pathways

- (P) UPD-glucuronsyl transferase
- (Q) ATP-sulfurylase & APS-Phosphokinase
- (R) Acyl synthatase & transacetylase
- (S) ATP-methioneine adensine transferase and methyl transferase
- (a) P-1, Q-4, R-3, S-2
- (c) P-3, Q-2, R-4, S-1

62. Group-I

Drug

- (P) Levofloxacine
- (Q) Econazole
- (R) Pentostatine
- (S) Procarbazine
- (a) P-3, Q-2, R-1, S-4
- (c) P-1, Q-2, R-4, S-3

63. Group-I

Terms

- (P) Saturated air
- (Q) Dew point
- (R) Humid volume
- (S) Humidity
- (a) P-1, Q-4, R-2, S-3
- (c) P-3, Q-1, R-4, S-2

Group- II

Types

- (1) N-methylation
- (2) Sulphate conjugation
- (3) Glucuronidation
- (4) Aminoacid conjugation
- (b) P-2, Q-3, R-1, S-4
- (d) P-4, Q-1, R-2, S-3

Group-II

Mechanism

- (1) Inhibits adenosine deaminase
- (2) Inhibits topoisomerase II
- (3) Forms adducts with DNA
- (4) Interferes with aminoacid transport by action on the membrane
- (b) P-2, Q-4, R-1, S-3
- (d) P-4, Q-2, R-3, S-1

Group-II

Explanation

- (1) Pounds of water vapour carried by one pound of dry air under any given set of conditions
- (2) The water vapour is in equilibrium with liquid Water at the given conditions of temperature and pressure
- (3) The volume is cubic feet occupied by one Pound of dry air and its accompanying water vapour
- (4) Temperature to which a mixture of air and Water vapour must be cooled in order to Become saturated
- (b) P-4, Q-3, R-1, S-2
- (d) P-2, Q-4, R-3, S-1

64. Group-I

Antibiotic

- (P) Bleomycin
- (Q) Nystatin
- (R) Carbenicillin
- (S) Streptomycin
- (a) P-2, Q-4, R-1, S-3
- (c) P-3, Q-2, R-4, S-1

65. Group-I

Pathoimmunological condition

- (P) Uraticaria
- (Q) Autoimmune thrombocytopenia
- (R) Rheumatoid arthritis
- (S) Organ transplant rejection
- (a) P-1, Q-2, R-4, S-3
- (c) P-3, Q-1, R-2, S-4

Group II

Test organism for microbiological assay IP

- (1) Pseudomonas areuginosa
- (2) Mycobaterium segmatis
- (3) Bacillus subtilis
- (4) Saccharomyces cerevisiae
- (b) P-4, Q-1, R-3, S-2
- (d) P-3, Q-1, R-2, S-4

Group-II

Drugs used in the treatment

- (1) Cyclosporin
- (2) Anthihistamines
- (3) Intravenous immunoglobulin
- (4) Glucocorticoids
- (b) P-4, Q-1, R-3, S-2
- (d) P-2, Q-3, R-4, S-1

DATA FOR Q.66-80 ARE BASED ON THE STATEMENT/ PROBLE.CHOOSE THECORRECT ANSWER FOR QUESTION FROM THE OPTION A,B,C AND D

COMMON DATA FOR QUESTIONS 66,67

A sample of Cinnamoman zeylanicum purchased from the market was evaluated for its authencity.

66. It shows

- (a) Presence of cork and cortex
- (c) Absence of phloem fibres

- (b) Absence of cork and cortex
- (d) Presence of xylemparenchyma

67. Voltile oil should not be less than

- (a) 0.05%
- (b) 0.20%
- (c) 0.50%
- (d) 1.00%

COMMON DATA FOR QUESTIONS 68, 69, 70

Choroactiacid and hydrazine are treated with X to get semicarbazido acetic acid in which ring closure takes place to 1-amino hydantoin. It is subsequently treated with 2-duacetoxy methyl-5-nitrofuran to get nitrofurantoin.

68. Reagent 'X' is

- (a) Cuprous chloride
- (c) Silver nitrate

- (b) Potassium cyanate
- (d) Mercurous chloride

69. Its IUPAC name is

- (a) 1-(5-nitrofurfuryl)hydantoin
- (c) 1-(5-nitrofurfuryl amino)hydantoin
- (b) 1-(5-nitrofurfuryl hydroxy)hydantoin
- (d) 1-(5-nitrofurfuryl nitro)hydantoin
- 70. Its gastrointestinal tolerance can be improved without interfering with oral absorption by preparing a
 - (a) Solid dispersion

- (b) Prodrug
- (c) Large cyrsalline form (Macrodantian)
- (d) Suspension

COMMON DATA FOR QUESTIONS 71, 72

A compound 'X' with molecular formula C_2H_4O exhibits a strong absorption band at 1730 cm $^{-1}$ in IR spectrum. On reduction is converted into 'Y' which shows a strong band at 3640 cm $^{-1}$.

| -F- | | | | | |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|----------------|---------------------------|----------------------------|
| 71. | Assingn the band in X to | | | | |
| | (a) CH ₃ | (b) C=C | (c) | C=O | (d) CH ₂ C=O |
| 72. | The strong band in Y is do | ue to | | | |
| | (a) -C-C | (b) -C-O-C- | (c) | =CH ₂ | (d) -OH |
| | | COMMON DATA FOR Q | UEST | TION 73, 74, 75 | |
| | he management of asthm Bambuterol | a, the drugs used are sali | neter | ol , Zafirlukast, Budes | oide ,Nedocromil sodium |
| 73. | Zafirlukast acts as | | | | |
| | (a) b ₂ adrenoceptor agor | nist | (b) | Cysteinyl-leukotriene | receptor antagonist |
| | (c) Muscarinic receptor | antagonist | (d) | Antihistamine | |
| 74. | A prodrug of terbutaline | is | | | |
| | (a) Zafirlukast | | (b) | Salmeterol | |
| | (c) Bambuterol | | ` ′ | Nedocromil sodium | |
| 75. Warfarin interacts with this antiasthmatic drug and increases prothrombin time | | | | e | |
| | (a) Budesonide | (b) Zafirlukast | (c) | Salmeterol | (d) Bambuterol |
| | | COMMON DATA FOR Q | UEST | IONS 76, 77, 78 | |
| be c give | pharmaceutical industry, carried out. The complete es a crystalline product of face during evaporation. | recovery of solids is requ n evaporation. The liqui | ired. d ten | After filtration, the fil | trate, which is corrosive, |
| 76. | The suitable filtration equ | ipments is | | | |
| | (a) Plate and frame filter | press | (b) | Leaf filters | |
| | (c) Meta filters | | (d) | Membrane filters | |
| 77. | The filter aid used in the | above filtration is | | | |
| | (a) Sand | | (b) | Nylon fiber cloth | |
| | (c) Activatedcarbon | | (d) | Filter paper | |
| 78. | A suitable evaporator is | | | | |
| | (a) Falling filmevaporate | r | (b) | Forced circulation ev | aporator |
| | (c) Vertical | | (d) | Horizontal evaporato | r |
| | | | | | |

COMMON DATA FOR QUESTION 79, 80

Isoprenoid biosynthesis is involved in the production of many biologically important compounds such as cholesterol. Steroid hormones, Vitamin K, Vitamin E and bile acid.

| 79. I | НМ | G-CoA reductase, a k | ey enzyme in the p | athway, cataly: | zes | | |
|--------|-------------------------------------------------------------------------------|--------------------------------------------|----------------------|-----------------|--------------------------|-------------|--------------------------|
| (| (a) Side-chain cleavage in the conversion of cholesterol to steroid hormones. | | | | | | |
| (| (b) | The reduction of the | e thio-ester group | to an akohol ii | n mevalonate bio | synthesis. | |
| | (c) | The reduction of the | e hydroxyl group n | nevalonate to V | /itamin D. | | |
| (| (d) | Steroid condensatio | n reaction in biosy | nthesis of bile | acids. | | |
| 80. ′ | The | inhibition of HMG-C | CoA reductase is a s | trategy used in | n the treatment o | f | |
| (| (a) | Familial hypercholes | sterolemia | (b) | Vitamin K deficie | ency | |
| (| (c) | Inflammation in the | joints | (d) | Hepatic parench | nymal dise | as |
| | | LINKED ANSWER | R QUESTIONS : 0 | Q. 81a TO Q | 85b CARRY T | rwo ma | RKS EACH |
| State | mei | nts for linked Answe | er Questions 81a 8 | & 81b: | | | |
| 4 | A p | erson after orthopad | edic surgery is pre | scribed a sele | ctive COX-2 inhi | bitor | |
| 81a. T | Γhe | selective COX-2 inhib | oitor is | | | | |
| (| (a) | Ketorolac | (b) Refecoxib | (c) | Indomethacin | (d) | Naproxen |
| 81b. ′ | The | drug selected is not | be given, if the pat | ient is already | tacking | | |
| (| (a) | Antiallergic drugs | | (b) | Anxiolytic drugs | | |
| (| (c) | Antihypertensive di | rugs | (d) | Oral antidiabetion | c agents | |
| State | mei | nt for Linked Answe | er Questions 82a & | & 82b: | | | |
| | | rug solution has an ency was found to b | | 300 mg/10 ml | . When stored in | a refrige | rator for 30 days, its |
| 82a. ′ | The | e rate constant, assun | ning that the drugs | solution under | goes first order k | inetics, is | |
| (| (a) | 0.0366 day ⁻¹ | (b) 0.0074 day | 1 (c) | 0.0174 day ⁻¹ | (d) | 0.0506 day ⁻¹ |
| 82b. l | Half | f-life of thedrugs solu | ıtion, under these c | ondition is | | | |
| | (a) | 9.4 days | (b) 19 days | (c) | 47 days | (d) | 4.7 days |
| State | mei | nt for Linked Answe | er Questions 83a & | & 83b | | | |
| • | Gin | ger is a widely used | herbal drug, cont | aining many d | hemical constit | uents. | |
| 83a. ′ | The | pungent principal p | resent in it, is | | | | |
| (| (a) | Zingiberol | (b) Zingiberene | e (c) | Gingerol | (d) | Cineole |
| 83.b. | It's | decomposition produ | ict, on boiling with | 2% KOH is | | | |
| (| (a) | Zingiberone | | (b) | Shogaol | | |
| | (c) | Gingedio | | (d) | Gingediol acetat | e | |
| State | mei | nt for Linked Answe | er Questions 84a & | & 84b: | | | |

2,6-dimethylphenol and chloroacetone reaction gives 'X', whichon treatment with hydroxylamine and hydrochloric acid gives intermediate product. This on further treatment with Raney nickel in acid, givesthe final product.

84.a. The product 'X' is

- (a) 1-(2,6-Dimethyl phenoxy)-2-propanone
- (b) 1-(2,6-Dimethyl phenoxy)-2-butanone
- (c) 1-(2,6-Dimethyl phenoxy)-2-isopropanone
- (d) 1-(2,6-Dimethyl phenoxy)-2-pentanone

84b. The finalproduct is

- (a) 1-methyl-2-(2,6-xylyloxy) isopropylamine
- (b) 1-methyl-2-(2,6-xylyloxy) ethylamine
- (c) 1-methyl-2-(2,6-xylyloxy) buylamine
- (d) 1-methyl-2-(2,6-xylyloxy) pentylamine

Statement for Linked Answer Questions 85a & 85b:

An organic compound 'X' has an absorption maxima at 217 nm. Its e_{\max} is 16,000. The absorbance is 0.64 when the cell length is 1 cm.

85a. The molar concentration of 'X' is

- (a) 5×10^{-5}
- (b) 4×10^{-5}

- (c) 4×10^{-4}
- (d) 5×10^{-2}

85b. The moral weight is 56.06, its concentration in gms/ml is

- (a) 2.5×10^{-6}
- (b) 0.25×10^{-6}
- (c) 5×10^{-5}
- (d) 2.24×10^{-6}

End of paper

ANSWER KEY GATE 2005

| 1 - b | 2 - c | 3 – d | 4 – b | 5 – a | 6 – c |
|-----------|-----------|-----------|---------------|-----------|---------------|
| 7 – d | 8 – c | 9 – a | 10 – d | 11 – b | 12 – b |
| 13 - с | 14 – b | 15 – d | 16 - c | 17 – a | 18 - c |
| 19 – d | 20 – a | 21 – c | 22 – b | 23 – d | 24 – b |
| 25 – a | 26 – b | 27 – b | 28 – c | 29 – d | 30 – b |
| 31 – a | 32 – a | 33 – d | 34 – a | 35 – c | 36 – b |
| 37 – b | 38 – d | 39 – b | 40 – a | 41 – b | 42 – b |
| 43 – b | 44 – d | 45 – a | 46 - a | 47 – b | 48 - d |
| 49 – b | 50 – a | 51 – c | 52 – a | 53 – a | 54 – b |
| 55 – b | 56 – a | 57 – c | 58 – b | 59 – b | 60 – b |
| 61 – c | 62 – b | 63 – d | 64 – a | 65 – d | 66 – b |
| 67 – d | 68 – b | 69 – c | 70 – c | 71 – c | 72 – d |
| 73 - b | 74 – c | 75 – b | 76 – a | 77 – a | 78 – a |
| 79 – b | 80 – a | 81 – a, b | 81 - b, c | 82 – a, a | 82- b, b |
| 83 – a, c | 83 – b, b | 84 – a, a | 84 – b, b | 85 – a, b | 85 – b, d |